The research objective of Stephen T. Turner, M.D., is to assess whether knowledge about variation in genes improves the ability to predict the risk of hypertension, the development of hypertensive complications, or the response to therapeutic or preventive interventions beyond what is provided by measurement of traditional biochemical, physiological or anthropomorphic predictor traits.
- Phenotype-to-genotype gene identification
- Genotype-to-phenotype gene identification
- Identification of genes involved in the control of blood pressure, hypertensive complications and responses to therapy
Significance to patient care
Hypertension is the most potent risk factor for heart attack and stroke, which are (respectively) the first and third most common causes of death in the U.S. It is also the most frequent indication for prescription medications.
Identifying genetic variants contributing to hypertension, the risk of target organ damage and responses to antihypertensive drug therapy has the potential to revolutionize diagnosis, evaluation and treatment of hypertension and reduce the public health burdens of heart attack and stroke.
See my publications
- Consultant, Division of Nephrology & Hypertension, Department of Internal Medicine
- Consultant, Department of Cardiovascular Medicine
- Professor of Medicine
- Fellow - Nephrology, research laboratory of Thomas P. Dousa, MD, PhD Mayo Graduate School of Medicine, Mayo Clinic College of Medicine
- Fellow - Nephrology Mayo Graduate School of Medicine, Mayo Clinic College of Medicine
- Resident - Internal Medicine University of Cincinnati Medical Center
- Internship - Internal Medicine University of Cincinnati Medical Center
- MD University of Cincinnati
- BA - Mathematics Brown University